All In Biotech

Free tool

FAERS Monitor: Juluca

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210192 or its brand name (Juluca, Dolutegravir Sodium, Rilpivirine Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

1,764

Serious

926

52% of reports

Hospitalization

318

Death reported

98

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • pain312
  • product dose omission issue296
  • anxiety285
  • emotional distress278
  • anhedonia251
  • chronic kidney disease204
  • renal failure132
  • fatigue125
  • depression120
  • osteoporosis92
  • acute kidney injury88
  • economic problem84
  • bone density decreased83
  • end stage renal disease83
  • renal impairment77

Reports by year received

View as table
YearReports
20164
20171
2018153
2019263
2020218
2021171
2022240
2023247
2024218
2025189
202660

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,395 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
anhedoniaSignal251115.0102.528,008
economic problemSignal8466.453.95,323
end stage renal diseaseSignal8354.544.24,290
chronic kidney diseaseSignal20432.128.26,121
bone density decreasedSignal8331.725.72,431
emotional distressSignal27827.424.67,081
osteoporosisSignal9226.721.92,252
product dose omission issueSignal29612.010.83,017
anxietySignal28512.010.72,885
renal failureSignal13211.910.11,309
renal impairmentSignal7710.98.8687
acute kidney injurySignal886.95.6438
depressionSignal1206.35.3534
painSignal3126.15.51,352
fatigue1251.91.656

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.